ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 1, 2023, at a meeting of the Board of Directors (the “Board”) of Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”), the Board elected Prof. Varda Shalev to serve as a member of the Board, effective September 1, 2023, until Teva’s 2024 annual meeting of shareholders. The Board determined that Prof. Shalev qualifies as an independent director under the listing rules of the New York Stock Exchange.
Prof. Shalev is a healthcare executive, medical researcher, and digital health investor with 30 years of experience in primary care, medical informatics, and health technology. Since 2022, Prof. Shalev has been a Managing Partner at Team8 Health, a leading Venture Capital firm in Israel that invests and builds disruptive and innovative healthcare technologies. Since 2020, she has also been a Co-Founder and an Advisory Board Member at Alike.Health, a digital health startup aiming to revolutionize patient care through technology. Prof. Shalev has been a Full Professor of Epidemiology at the Tel Aviv University School of Public Health since 2013 and an active primary care physician since 1993. Prior to her current roles, Prof. Shalev founded and led KSM, the Research and Innovation Center of Maccabi Health Services. She also founded the largest Biobank in Israel at Maccabi Healthcare Services.
Prof. Shalev has served as a board member at BATM Advanced Communications Ltd. since 2019 and at Novolog Pharm up 1966 Ltd. since 2022.
Prof. Shalev has declared in writing that she possesses the requisite skills and expertise, as well as sufficient time, to perform her duties as a director of Teva, as required pursuant to the Israeli Companies Law, 5759-1999.
Prof. Shalev will receive the same compensation as Teva’s other non-executive directors, which is described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 19, 2023.
There are no arrangements or understandings between Prof. Shalev and any other persons pursuant to which Prof. Shalev was elected as a director of the Board. Prof. Shalev does not have a direct or indirect material interest in any related party transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. There are no family relationships between Prof. Shalev and any director or executive officer of the Company.